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Traumatic brain injury (TBI) is a disease with high morbidity and leads to high rate of disability and mortality. 
The blood-brain barrier (BBB) damage is an important pathological change in brain after TBI, which impacts 
the development and prognosis of the disease. In our previous research, we have reported that miR-21-5p in 
neurons can exert an anti-apoptosis effect, and promote the restoration of injured BBB after TBI. Up-regulation 
of miR-21-5p level in brain can amplify the above functions of miR-21-5p, thus alleviate BBB damage and 
improve the neurological prognosis of TBI. miR-21-3p, which is generated from pre-miR-21 at the same time 
with miR-21-5p, has been reported to play significant roles in regulating cellular apoptosis, 
immuno-inflammatory responses and the expression of angiogenic factors in various diseases. We made a 
summary of previous research on miR-21-3p and inferred that miR-21-3p could exert an important impact on 
BBB damage after TBI. Taken together, miR-21 is a vital miRNA that impacts the restoration of injured BBB, 
thus it could be a potential therapeutic target for interventions in TBI. 
Keywords: traumatic brain injury; miR-21; blood-brain barrier 
To cite this article: Xintong Ge, et al. miR-21, a potential therapeutic target of alleviating blood-brain barrier damage after 
traumatic brain injury. RNA Dis 2015; 2: e642. doi: 10.14800/rd.642. 
Traumatic brain injury (TBI) is the leading cause of 
long-term disability in children and young adults. About 10 
million people are affected by a new TBI event every year 
around the world [1]. With the development of urbanization, 
the increase of traffic accidents and regional wars, the 
incidence of TBI is increasing rapidly in recent years [2]. 
Scientists predict that TBI will be the third largest cause of 
worldwide disease by 2020 [3]. 
Elucidating the pathological changes involved in TBI and 
improving the clinical treatment level for TBI has long been 
important issues for neuroscientists and neurosurgeons. The 
primary insult leads to not only primary brain damage 
(including cerebral contusion and laceration, extradural 
hematoma, subdural hematoma, intracranial hemorrhage, 
subarachnoid hemorrhage, etc.), but also a series of 
pathological events like immuno-inflammatory responses 
and cellular apoptosis/necrosis in brain [4]. These pathological 
events interact with each other and develop concurrently. 
They result in secondary brain damage, which mainly 
includes nerve cells apoptosis, impaired local blood supply 
and BBB damage [5]. The BBB damage is an important 
pathological change in brain that it is a significant cause of 
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serious complications of TBI, like brain edema, intracranial 
infection and subsequent neurological dysfunction [6]. As the 
primary insult cannot be therapeutically influenced, 
promoting the restoration of injured BBB is crucial for 
treating and improving the prognosis of TBI. 
The clinical therapeutic methods for TBI mainly includes 
oxygen inhalation therapy, decompressive craniectomy, 
evacuation of intracranial hematoma, dehydrant and 
neurotrophic drug treatment. As these methods are not aimed 
at directly alleviating BBB damage, their therapeutic effects 
are limited in controlling secondary brain damage. The 
high-dose glucocorticoid pulse therapy was supposed to be 
effective in alleviating BBB damage after TBI. However, a 
clinical trail (MRC CRSAH) involved 10008 patients 
conducted in more than 40 countries demonstrated that 
corticosteroids does not have any therapeutic effect on TBI 
patients in spite of the time of administration post-injury [7]. 
Our previous research also proved that high-dose 
methylprednisolone can aggravate cellular apoptosis and 
BBB damage in hypothalamus, which can exacerbate the 
acute critical illness-related corticosteroid insufficiency 
associated with TBI [8-9]. Molecular therapy for TBI has 
become the research hotspot in recent years. The function of 
erythropoietin, progesterone and other molecules in 
alleviating BBB damage have been widely confirmed in 
animal models. However, these therapeutic methods are not 
effective in TBI patients according to the reports of clinical 
trials [10, 11]. Therefore, exploring new therapeutic strategies 
for alleviating BBB damage is crucial for the clinical 
treatment of TBI. 
miR-21 is a non-protein coding RNA molecule that 
negatively modulate the expression of its target proteins. It 
has been proved to be an oncogene and implicated in the 
etiology of a variety of diseases, like cancer and 
cardiovascular diseases. However, little attention has been 
paid to their roles in acute diseases, such as TBI. Mature 
miR-21 includes miR-21-5p and miR-21-3p. They are both 
generated from pre-miR-21 at the same time through several 
steps of enzyme digestion [12]. As to the previous research on 
miR-21-5p, Redell [13] and our group [14] have detected the 
miRNAs change in brain of TBI rats using miRNAs profiling 
and qRT-PCR, indicating that the expression level of 
miR-21-5p in the hippocampus and injured cerebral cortex 
were both increased from 6 h to 72 h post-injury. PDCD4 and 
Tiam1 were predicted to be the target genes of miR-21-5p 
after TBI [14]. These findings suggest that miR-21-5p is a 
potential biomarker and therapeutic target in TBI. In addition, 
Sandhir [16] found that miR-21-5p showed no increased 
expression in response to injury in aging mice following TBI, 
and the expression of its target genes, including PTEN and 
PDCD4, were up-regulated. As the activation of PTEN and 
PDCD4 can promote cellular apoptosis, the diminished 
miR-21-5p injury response may contribute to the poor 
prognosis of aged mice compared to the adult. Consequently, 
strategies aimed at up-regulation of miR-21-5p and/or down 
regulation of its targets might be useful in improving 
outcomes following TBI. 
Since 2009, we has performed a series of research on the 
function and mechanism of miR-21 in TBI. We have proved 
that neurons-expressed miR-21-5p exerted an anti-apoptosis 
effect in brain after TBI, thereby promoting the restoration of 
injured BBB and improving the neurological prognosis of 
TBI [15, 17-19]. Specifically, we employed the fluid percussion 
injury rat model, and detected the expression level of 
miR-21-5p in the traumatic focci using qRT-PCR. We found 
that the miR-21-5p level was increased from 6 h to 72 h 
post-injury, and it can be further up-regulated or 
down-regulated by intracerebroventricularly injection of 
miR-21-5p agomir or antagomir [18]. We then measured the 
expression of miR-21-5p in neurons, astrocytes, microglias 
and brain microvascular endothelial cells (BMVECs) 
respectively using combined miRNA in-situ hybridization 
and immunofluorescence. We found that compared to 
astrocytes and microglias, neurons and BMVECs expressed 
more miR-21-5p, and their miR-21-5p levels are more 
sensitive in response to injury [18]. We evaluated the influence 
of miR-21-5p on the neurological outcome of TBI rats using 
modified neurological severity score and Morris Water Maze. 
We found that the increased miR-21-5p level in brain 
post-injury was beneficial for improving the neurological 
prognosis of TBI [18]. Then, we observed the impact of 
miR-21-5p on cellular apoptosis in rats and in-vitro cultured 
neurons to investigate the mechanism of its protective effect 
in TBI. We confirmed that miR-21 inhibited apoptosis in 
neurons through inhibiting PTEN expression at the 
post-transcriptional level and activating Akt signaling [18-19]. 
In addition, we evaluated the impact of miR-21-5p on BBB 
damage by measuring brain water content, the amount of 
Evan’s Blue extravasation and the expression level of tight 
junction proteins in brain. We demonstrated that miR-21-5p 
can alleviate BBB damage by activating Ang-1/Tie-2 axis. 
And this effect is also associated with its inhibition on 
cellular apoptosis in brain [17-18]. Taken together, 
up-regulation of miR-21-5p level in brain can inhibit the 
cellular apoptosis and alleviate BBB damage, thus improve 
the neurological prognosis of TBI. 
Recently, the biological function of miRNA* in various 
diseases began to drawn increasing attention from scientists. 
As to miR-21-3p (miR-21*), it has been confirmed that its 
expression is significantly up-regulated in various tumor 
cells, including non-small cell lung cancer [20], colorectal 
cancer [21] and several human carcinomas [22]. Besides, 
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miR-21-3p can activate the Akt signaling that regulates 
cellular apoptosis in breast tumors [23]. The research on 
human aortic endothelial cells also found that miR-21-3p is 
an up-stream regulator of NF-kB signaling that can regulate 
the immuno-inflammatory responses [24]. In the research on 
cardiac hypertrophy, miR-21-3p has been proved to have the 
function of impacting the hypertrophic progress of 
cradiomyocytes induced by Ang-2 infusion, suggesting that 
miR-21-3p could regulate the expression of angiogenic 
factors, such as Ang-1 and Ang-2 [25-26]. Taken together, 
miR-21-3p may possibly have the function of regulating 
cellular apoptosis, immuno-inflammatory responses and the 
expression of angiogenic factors in brain. From this, we 
inferred that miR-21-3p could exert an important impact on 
BBB damage after TBI. And we have planned to study the 
function and mechanism of miR-21-3p in regulating the 
restoration of BBB damage in the future. 
In conclusion, miR-21 is a vital miRNA that impacts the 
restoration of injured BBB, thus it could be a potential 
therapeutic target for interventions in TBI. The outcome of 
our work has further elucidated the mechanism of BBB 
damage and restoration, and also provided insights into 
developing a novel therapeutic strategy for TBI. 
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